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Circulating microRNAs (miRNAs) are emerging as promising biomarkers for several 19 
disorders and related pain. In equine practice, acute laminitis is a common disease 20 
characterised by intense pain that severely compromises horse welfare. Recently, the 21 
Horse Grimace Scale (HGS), a facial-expression-based pain coding system, was shown to 22 
be a valid welfare indicator to identify pain linked to acute laminitis. The present study 23 
aimed to: determine whether miRNAs can be used as biomarkers for acute pain in horses 24 
(Equus caballus) affected by laminitis; integrate miRNAs to their target genes and to 25 
categorise target genes for biological processes; gather additional evidence on concurrent 26 
validity of HGS by investigating how it correlates to miRNAs. Nine horses presenting acute 27 
laminitis with no prior treatment were recruited. As control group, nine healthy horses were 28 
further included in the experimental design. Samples were collected from horses with 29 
laminitis at admission before any treatment (“pre-treatment”) and seven days after routine 30 
laminitis treatment (“post-treatment”). The expression levels of nine circulating miRNAs, 31 
namely hsa-miR-532-3p, hsa-miR-219-5p, mmu-miR-134-5p, mmu-miR-124a-3p, hsa-32 
miR-200b-3p, hsa-miR-146a-5p, hsa-miR-23b-3p, hsa-miR-145-5p and hsa-miR-181a-5p, 33 
were detected and assessed as potential biomarkers of pain by qPCR using TaqMan® 34 
probes. The area under the receiver operating curve (AUC) was then used to evaluate the 35 
diagnostic performance of miRNAs. Molecular data were integrated with HGS scores 36 
assessed by one trained treatment and time point blind veterinarian. The comparative 37 
analysis demonstrated that the levels of miR-23b-3p (P = 0.029), miR-145-5p (P = 0.015) 38 
and miR-200b-3p (P = 0.023) were significantly higher in pre-treatment and the AUCs 39 
were 0.854, 0.859 and 0.841, respectively. MiR-200b-3p decreased after routine laminitis 40 
treatment (P = 0.043). Combining two miRNAs in a panel, namely miR-145-5p and miR-41 
200b-3p, increased efficiency in distinguishing animals with acute pain from controls. In 42 
addition, deregulated miRNAs were positively correlated to HGS scores. Computational 43 
target prediction and functional enrichment identified common biological pathways 44 
between different miRNAs. In particular, the glutamatergic pathway was affected by all 45 
three miRNAs, suggesting a crucial role in the pathogenesis of pain. In conclusion, the 46 
dynamic expression of circulating miR-23b-3p, miR-145-5p and miR-200b-3p was detected 47 
in horses with acute laminitis and miRNAs can be considered potentially promising pain 48 
biomarkers. Further studies are needed in order to assess their relevancy in other painful 49 
conditions severely compromising horse welfare. An important implication would be the 50 
possibility to use them for the concurrent validation of non-invasive indicators of pain in 51 
horses. 52 
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 55 
Implications  56 
Pain severely affects the welfare of horses and often remains underestimated. 57 
Measuring pain-related parameters in a reliable way can be challenging; however, an 58 
accurate determination and quantification of pain in horses is critical. Several 59 
physiological, endocrine and behavioural parameters have been investigated to identify 60 
pain conditions and severity in clinical studies. To date, no molecular indicators have been 61 
available to assess horse pain. Tackling the challenge of improving the welfare of horses 62 
affected by laminitis, the present study highlights the possible use of molecular biomarkers 63 
in assessing and quantifying pain in horses. Three candidate biomarkers have been 64 
identified in the serum of horses with acute laminitis. An integrated analysis between 65 
behavioural indicators (HGS) and molecular biomarkers could be used to assess and 66 
monitor painful conditions in horses. 67 
Introduction 68 
MiRNAs belong to a class of non-coding single-stranded RNA of 19–24 nucleotides with 69 
the ability to modulate gene expression post-transcriptionally. They are crucial modulators 70 
of cellular homeostasis and their deregulation has been associated with a wide range of 71 
pathological conditions and with neuropathic, inflammatory, traumatic and cancer-72 
associated pain in humans (Bali and Kuner, 2014; Zhang and Banerjee, 2015; Pang et al., 73 
2016) and laboratory animals (Gong et al., 2015; Pang et al., 2016; Qureshi et al., 2016). 74 
The modulation of miRNA expression is an early event in pathogenic processes 75 
(Schwarzenbach et al., 2014). They act by guiding the RNA-induced silencing complex 76 
(RISC) to partially complementary sequences in target mRNA to suppress gene 77 
expression by a combination of translation inhibition and mRNA decay (Lagos-Quintana et 78 
al., 2001). The level and composition of extracellular miRNAs in certain body fluids are 79 
tightly correlated to various human pathological conditions, such as cancer, diabetes, 80 
cardiovascular diseases and drug-induced organ damage (Ghai and Wang, 2016). A 81 
change in the expression pattern of miRNAs targeting key regulators of pain processing 82 
has been observed both in inflammatory and neuropathic pain (Zhao et al., 2010; Genda 83 
et al., 2013). Although some investigations have already evaluated miRNAs as suitable 84 
biomarkers to assess stress associated with endurance exercise in horses (Mach et al., 85 
2016) and with road-transportation in turkeys (Lecchi et al., 2016), the diagnostic potential 86 
of circulating miRNAs deserves to be further explored in veterinary medicine in relation to 87 
stressful or painful conditions that might affect animal welfare.  88 
Acute laminitis is a disease associated with ischaemia of digital dermal tissues whose 89 
exact aetiology is still not completely understood (Wylie et al., 2013). However, there are 90 
evidences that support a possible link between insulin resistance, obesity, and acute 91 
laminitis (Geor, 2008). Evidences suggest that the pain state associated with chronic 92 
equine laminitis have a neuropathic component (Jones et al., 2007) indicating that both 93 
inflammatory and neuropathic pain should be considered in the management of this 94 
condition. In equine practice, acute laminitis provides a valuable pain model as it severely 95 
affects animal welfare causing severe, long-lasting debilitating pain in horses (Dalla Costa 96 
et al., 2014b; Minero and Canali, 2009). Since 2010, World Horse Welfare, an international 97 
horse charity, has launched a campaign about the importance of recognising the early 98 
signs of laminitis to protect horse welfare and minimise the associated pain. This disease 99 
has a worldwide estimated prevalence of 7–14% and is characterised by lameness, 100 
inability or reluctance to walk, frequent weight shifting, and abnormal weight distribution on 101 
hind feet (Collins et al., 2010; Wylie et al., 2013). Albeit challenging, accurate pain 102 
assessment is critical to recognise early signs associated with laminitis (e.g. strong digital 103 
pulse, shortening of the stride, abnormal foot lifting (Wylie et al., 2013)) and ensure 104 
appropriate treatment (de Grauw and van Loon, 2016). Among commonly used systems, 105 
the Composite Pain Scale (CPS), a multifactorial numerical rating scale, considers 106 
physiological response to treatment and behavioural data. The CPS was originally 107 
developed on an experimental model of acute orthopaedic pain in horses (Bussières et al., 108 
2008) and then applied to monitor pain after surgery (e.g. castration, colic, orthopaedic 109 
and soft-tissue surgery) (Van Loon et al., 2010). Recently, a facial-expression-based pain 110 
coding system, the Horse Grimace Scale (HGS) was developed as a welfare indicator for 111 
pain assessment of horses undergoing surgical castration (Dalla Costa et al., 2014a) and 112 
acute laminitis (Dalla Costa et al., 2016). HGS is a fast method based on behavioural 113 
observation. It does not cause disturbance to the horses in their boxes, does not require 114 
their walking and/or trotting as well as any palpation of their painful area. HGS has 115 
potential to provide insights into the experience of pain in horses and in the assessment of 116 
horse welfare, however, the authors concluded that further validation studies were needed 117 
to apply the HGS in a clinical setting (Dalla Costa et al., 2017, 2016, 2014a). Considering 118 
the diagnostic potential of miRNAs and the evidence of their identification in the equine 119 
genome, tissues and serum (Kim et al., 2014; Pacholewska et al., 2016), the aims of the 120 
present study were to a) ascertain whether acute pain associated with laminitis may 121 
modulate the expression of circulating miRNAs; b) investigate the potential use of 122 
differentially expressed (DE)-miRNAs as biomarkers to measure pain in horses and c) 123 
gather additional evidence on concurrent validity of HGS and CPS by investigating how 124 
they correlate with miRNAs. 125 
 126 
Materials and methods 127 
Ethics statement 128 
The study design was approved by the Brandenburg State Veterinary Authority (V3-2347-129 
A-42-1-2012) in compliance with German legislation on animal experiments. Individual 130 
horse owner’s consent was obtained for all horses participating in this study. Horses 131 
involved in this study were admitted for routine veterinary treatment of acute laminitis at 132 
the request of their owner on a voluntary basis. Control samples were obtained from 133 
healthy stallions referred to the clinic for surgical castration. 134 
 135 
Animals and husbandry 136 
Between 2012 and 2014, horses admitted to the Havelland Equine Clinic presenting acute 137 
laminitis with no prior treatment were included in the present study. Nine horses of 138 
different breed and gender, aged between 4 and 17 years (mean=9.4±5.0) were recruited. 139 
As a control group, nine healthy stallions of mixed age (mean=2.4±1) referred to the clinic 140 
for routine castration were recruited. In order to be included in this study, control horses 141 
had to be deemed healthy by an equine veterinarian after physical examination and 142 
behavioural evaluation. All horses, after admission, were stabled in standard single boxes 143 
(4 x 3 m with an outside window) on wood shavings (German Horse Span Classic, 144 
German Horse Pellets, Wismar Germany), and in visual contact with conspecifics. They 145 
were fed hay twice a day (approx. 3 kg/100kg body weight per day) and water was 146 
provided ad libitum by automatic drinkers.  147 
Each horse with laminitis underwent a routine treatment including: oral administration of 148 
Phenylbutazone (initial 4.5 mg/kg bwt every 12 h for two days and subsequent 2.5 mg/kg 149 
bwt every 12 h, Phenylbutariem®, Ecuphar, Germany); subcutaneous injections of heparin 150 
(50 IU/kg bwt every 12 h for five days, Heparin-Natrium-25000-ratiopharm®, Ratiopharm, 151 
Germany); padded hoof bandages with frog support and elevated heels (3 – 4 cm); ice 152 
water applications every 2 h for the first three days of treatment and strictly restricted 153 
movement in an individual box with a deep and soft bedding of wood shavings. 154 
Horses with acute laminitis were assessed, as described in the following sections, at 155 
admission before any treatment (“pre-treatment”) and seven days after the treatment, 156 
before being discharged (“post-treatment”). Control horses (“control”) were assessed once, 157 
after 2 days of acclimatisation to the clinic setting and before surgery. Assessments were 158 
carried out in the morning between 8 and 12. Horses were monitored routinely at least 3 159 
times a day, or more frequently if needed, by an experienced vet or nurse by collecting 160 
data about HR, breath frequency, appetite, defecation, weight shifting and obvious signs of 161 
pain.  162 
MiRNAs extraction and real-time quantitative PCR 163 
Blood was collected by jugular venipuncture into Monovette® tubes (Sarstedt Company, 164 
Nümbrecht, Germany) and serum was stored at -80°C until RNA extraction. Total RNA 165 
was extracted using miRNeasy Serum/Plasma Kit (Qiagen, catalog number 217184). 166 
Serum was thawed on ice and centrifuged at 3000 g for 5 min at 4°C. An aliquot of 200 µl 167 
per sample was transferred to a new tube and 1 ml of Qiazol (Qiagen) was added. The 168 
Caenorhabditis elegans miRNA cel-miR-39 (Qiagen, catalog number 219610) was used as 169 
synthetic spike-in control because of a lack of sequence homology to equine miRNAs. 170 
After incubation at room temperature for 5 min, 3.75 µl (25 fmol final concentration) of 171 
spike-in control was added and the samples were vortexed to ensure complete mixing. 172 
RNA extraction was then carried out according to manufacturer’s instruction. Reverse 173 
transcription was performed using the TaqMan MicroRNA Reverse Transcription Kit 174 
(Applied Biosystems, catalog number 4366596) and using miRNA-specific stem-loop RT 175 
primers, according to manufacturer’s instructions. Reverse transcription reactions were 176 
performed in 15 μl volume reactions containing 1.5 µl 10X miRNA RT buffer, 1 µl 177 
MultiScribe reverse transcriptase (50 U/µl), 0.30 µl 100 mM dNTP mix, 0.19 µl RNase 178 
Inhibitor (20 U/µl), 6 μl of custom RT primer pool and 3.01 µl of nuclease-free water. The 179 
custom RT primer pool was prepared combining 10 µl of each individual 5X RT primer in a 180 
final volume of 1000 µl; the final concentration of each primer in the RT primer pool was 181 
0.05X each. Three μl serum RNA was added to each RT reaction. Every RT reaction 182 
mixture was incubated on ice for 5 minutes, 16°C for 30 minutes, 42°C for 30 minutes and 183 
then 85°C for 5 minutes.  184 
The qPCR experiments were designed following the MIQE guidelines. Small RNA TaqMan 185 
assays were performed according to manufacturer’s instruction. MicroRNAs were selected 186 
according to previous publications where they were correlated to pain in humans and mice 187 
(Elramah et al., 2014; Bali and Kuner, 2014; Qureshi et al., 2016). The selected 188 
primer/probe assays (Life Technologies) included cel-miR-39-3p (assay ID000200), hsa-189 
miR-532-3p (assay ID002355), hsa-miR-219-5p (assay ID00522), mmu-miR-134-5p 190 
(assayID001186), mmu-miR-124a-3p (assay ID001182), hsa-miR-200b-3p (assay 191 
ID002251), hsa-miR-146a-5p (assay ID000468), hsa-miR-23b-3p (assay ID000400), hsa-192 
miR-145-5p (assay ID002278) and hsa-miR-181a-5p (assay ID000480). Quantitative 193 
reactions were performed in duplicate in scaled-down (12 µl) reaction volumes using 6 µl 194 
TaqMAN 2X Universal Master Mix II (Applied Biosystems, catalog number 4440044), 0.6 195 
µl miRNA specific TaqMan Assay 20X and 1µl of the RT product per reaction on Eco Real 196 
Time PCR detection System (Illumina). The standard cycling program was 50°C for 2 min, 197 
95°C for 10 min and 40 cycles of 95°C for 15 sec and 60°C for 60 sec. Data were 198 
normalized relative to the expression of cel-miR-39. MiRNAs expression levels are 199 
presented in terms of fold change normalized to cel-miR-39 expression using the formula 200 
2-∆∆Cq. To investigate the pain relevance, predicted targets of the significant DE-miRNAs 201 
were computationally retrieved from the TargetScan database 202 
(http://www.targetscan.org/vert_71/) and mRNA enrichment was performed using DAVID 203 
bioinformatics resources (https://david.ncifcrf.gov/). The list of target genes was employed 204 
in further analyses and biological pathways in the KEGG were examined for enrichment 205 
(http://www.genome.jp/kegg/). Since alterations in neuronal excitability are believed to 206 
contribute to the initiation and maintenance of neuropathic pain following peripheral injury, 207 
an enrichment of mRNA targets that encode for ion channels - known to contribute and 208 
modulate neuronal excitability - was performed. Based on knockout studies, the predicted 209 
mRNA targets have already been associated with hypersensitivity in various pain models 210 
(http://www.jbldesign.com/jmogil/enter.html) (LaCroix-Fralish et al., 2007).  211 
 212 
Behavioural recordings  213 
An experienced veterinarian conducted the live evaluation of the Composite Pain Scale 214 
(CPS) developed by Bussières and colleagues (2008) with slight modifications, as 215 
previously reported (Dalla Costa et al.,2014a). Twenty-minute videos were simultaneously 216 
recorded using two video cameras (Panasonic, HDC-SD99, Panasonic, Japan). In order to 217 
collect videos without influencing the horse’s behaviour, the video cameras were 218 
positioned on the opposite sides of the box on top of their grate section. Following the 219 
methods of Dalla Costa and colleagues (2014a), where images (one or two per animal) 220 
per time point were included, still frames of the face of each horse were extracted from the 221 
videos whenever they directly faced the video camera. The selection was based on the 222 
quality of the picture. On a sample of 27 still images (9 for control horses, 9 for pre-223 
treatment and 9 for post-treatment), randomly selected by a non-participating assistant, 224 
the HGS was assessed by one trained treatment and time point blind veterinarian (not 225 
involved in the CPS assessment). A detailed handout with the description of the six Facial 226 
Action Units (FAUs) was used as training material. FAUs are independently scored on a 3-227 
point scale, with zero indicating that the assessor is confident that the action unit is not 228 
present, one indicating that the assessor is confident that the action unit is only moderately 229 
present, and two indicating that the assessor is confident that the action unit is obviously 230 
present. The possible maximum HGS score was 12 (2 for each FAUs). 231 
 232 
Statistical analysis  233 
Statistical analysis was performed using SPSS 23 (SPSS Inc., Chicago, IL, USA). 234 
Statistical significance was accepted at P ≤ 0.05. The CPS total score was calculated. The 235 
HGS total score for each image consisted of the sum of the scores across the six FAUs. 236 
Data were tested for normality and homogeneity of variance using the Kolmogorov-237 
Smirnov and Levene test, respectively. As data were not normally distributed, non-238 
parametric statistical tests were applied. Mann Whitney test was used to assess 239 
differences in miRNAs concentrations (only for those miRNAs that had a significant 240 
differential expression in the blood of horses), CPS and HGS scores between control 241 
group and pre-treatment group, and control and post-treatment group. Match paired 242 
Wilcoxon test was run to compare miRNA concentrations (miR-23b-3p, miR-145-5p and 243 
miR-200b-3p), CPS and HGS scores pre- and post-treatment. Receiver Operating 244 
Characteristic (ROC) analysis was performed to determine the diagnostic accuracy of 245 
targets that statistically differed between pre-treatment and controls. The diagnostic values 246 
were calculated for those miRNAs (alone and in combination) that showed a significant 247 
differential expression in the blood of horses, namely miR-23b-3p, miR-145-5p and miR-248 
200b-3p. The ROC analysis was carried out by plotting the true positive (sensitivity) versus 249 
the false positive (1-specificity). Linear regression was used to investigate any relationship 250 
between miR-23b-3p, miR-145-5p and miR-200b-3p and age of the horses. Spearman’s 251 
rho test was performed to evaluate whether there was any correlation among the 252 
expression levels of the various miRNAs, HGS and CPS. 253 
 254 
Results 255 
Acute laminitis alters expression levels of miR-23b-3p, miR-145-5p and miR-200b-3p in 256 
blood serum 257 
The levels of miRNAs were normalized to the levels of the artificial spike-in cel-miR-39, 258 
which was used as internal control. The selected target miRNAs were detected in all 259 
samples, with exception of the miRNAs has-miR-219-5p, has-miR-532-3p, mmu-miR-134-260 
5p and mmu-miR-124a-3p. Statistical analyses was performed on detected five miRNAs, 261 
among which 3 circulating miRNAs, namely miR-23b-3p, miR-145-5p and miR-200b-3p, 262 
had a significant differential expression in the blood of horses. Figure 1 presents an 263 
overview of the results. In detail, the level of miR-23b-3p (fold change=14.6; P = 0.029), 264 
miR-145-5p (fold change=4.4; P = 0.015) and miR-200b-3p (fold change=3.4; P = 0.023) 265 
was higher in pre-treatment compared to controls. Only miR-200b-3p significantly 266 
decreased from pre- to post-treatment (Match paired Wilcoxon, P = 0.043). The levels of 267 
circulating miR-23b-3p, miR-145-5p and miR-200b-3p were not affected by the age of the 268 
horse (Linear regression, P > 0.05). 269 
 270 
Diagnostic performance of miR-23b-3p, miR-145-5p and miR-200b-3p 271 
Diagnostic accuracy of miR-23b-3p, miR-145-5p and miR-200b-3p, as measured by the 272 
area under the curve (AUC), was good for all targets for the discrimination of pre-treatment 273 
from controls (Figure 2) and it was 0.854 (95% CI 0.5652-1; P = 0.028), 0.859 (95% CI 274 
0.66-1; P = 0.016) and 0.841 (95% CI 0.643-1; P = 0.023), respectively.  275 
Further statistical analysis was performed considering the average relative quantification 276 
(RQ) values of the three pain-related miRNAs. The combination of miRNAs resulted in an 277 
improved discrimination of the pre-treatment. The created model included all three 278 
miRNAs (miR-23b-3p, miR-145-5p and miR-200b-3p) or two (miR-145-5p and miR-200b-279 
3p). The AUC from ROC analysis increased to 0.917 (95% CI 0.782-1; P = 0.004; 280 
sensitivity 100% and specificity 78%, cut-off 0.1936) and 0.917 (95% CI 0.773-1; P = 281 
0.004; sensitivity 87.5% and specificity 89%, cut-off 0.279), respectively.  282 
 283 
Composite Pain Scale (CPS) and Horse Grimace Scale (HGS) and their correlation to 284 
miRNAs 285 
Both CPS and HGS scores were significantly lower in the control group (Mann Whitney 286 
test, P < 0.001) than in horses with acute laminitis (pre-treatment) (Figure 3). Control 287 
horses did not differ from post-treatment for both CPS and HGS scores (Mann Whitney 288 
test, P = 0.167 and P = 0.059 respectively).  289 
A positive correlation was observed among miR-145-5p, HGS (R2= 0.482; P = 0.015) and 290 
CPS (R2= 0.575; P = 0.003). A positive correlation was also found between the 291 
combination of miR-145-5p and miR-200b-3p with both HGS (R2= 0.559; P = 0.004) and 292 
CPS (R2= 0.595; P = 0.002). 293 
 294 
miRNA target prediction and pathway enrichment 295 
The predicted mRNA targets were 97, three of which were regulated by all three miRNAs 296 
and 15 by at least two miRNAs (Figure 4A). The target mRNA are grouped in ion channel 297 
families: solute carrier family transporters (SLC), potassium voltage-gated channel (KCN), 298 
voltage-gated sodium channel (SCN), gamma-aminobutyric acid (GABA) A or B receptor 299 
(GABRB and GABBR), voltage-dependent calcium channel (CACN), adrenoceptor alpha 300 
(ADRA), potassium channel (tetramerization domain) (KCTD), hyperpolarization activated 301 
cyclic nucleotide-gated potassium channel (HCN), two pore segment channel (TPCN), 302 
transient receptor potential cation channel (TRP) (Figure 4B). The KEGG pathway analysis 303 
demonstrated that most of these genes code for proteins involved in the glutamatergic 304 
pathway (Figure 4C). 305 
 306 
Discussion 307 
The present study investigated the circulating levels of nine miRNAs and assessed 308 
their diagnostic value in serum of horses affected by acute laminitis. In particular, their 309 
incremental diagnostic value was investigated. We report five major findings. Firstly, 310 
circulating levels of miR-23b-3p, miR-145-5p and miR-200b-3p were significantly higher in 311 
animals with acute laminitis than in controls. Secondly, diagnostic accuracy for acute 312 
laminitis was good (0.80 < AUC < 0.90) for miR-23b-3p, miR-145-5p and miR-200b-3p. 313 
Thirdly, diagnostic accuracy of the combination of two or three differentially expressed 314 
miRNAs was excellent (0.90 < AUC < 1). Fourthly, the level of miR-200b-3p significantly 315 
decreased from pre- to post-treatment. Lastly, the correlation between miRNAs and other 316 
behavioural pain measures (HGS and CPS) was positive.  317 
Accurate determination of pain is crucial, given that it is often difficult to measure 318 
pain-related parameters in a quantitative way. In horses affected by acute laminitis, the 319 
common challenging question for clinicians is whether their level of pain and suffering is 320 
acceptable to continue their treatment. An important development in understanding pain 321 
level and mechanisms is represented by miRNAs (Bali and Kuner, 2014). The use of 322 
miRNAs as diagnostic and prognostic biofluid-derived markers is advancing in various 323 
fields, including oncology and cardiology. The presence of an altered circulating miRNA 324 
profile has been demonstrated for several painful conditions, including neuropathic, 325 
inflammatory, traumatic and cancer-associated pain in humans and rodents (Andersen et 326 
al., 2014; Qureshi et al., 2016). Recent studies reported that miRNome is involved in 327 
equine osteochondrosis physiopathology and quickly reacts to endurance exercise stress 328 
(Desjardin et al., 2014; Mach et al., 2016). Our results suggest that circulating levels of 329 
miR-23b-3p, miR-145-5p and miR-200b-3p were effective in accurately differentiating 330 
horses affected by acute laminitis from controls. To the best of our knowledge, the effect of 331 
Phenylbutazone on circulating miRNAs has never been investigated, while contradictory 332 
results have been reported on heparin. Some authors indicated that heparin might have an 333 
impact on the circulating level of miRNA expression in patients undergoing cardiac 334 
catheterisation (Kaudewitz et al., 2013), whereas others did not find any difference in 335 
patients with acute myocardial infarction (Wang et al., 2016). Our results showed that miR-336 
200b-3p upregulated by acute laminitis was restored by drug administration, suggesting 337 
that molecular changes induced by drugs can be assessed from serum. Thus, increased 338 
understanding of miRNA expression pattern in the serum of pain-affected animals would 339 
improve both pre-treatment evaluation and monitoring of the disease course.  340 
When facing intense and long lasting painful diseases, such as laminitis, a combination of 341 
non-invasive pain measures and molecular biomarkers should be considered in the 342 
attempt of increasing the overall accuracy of the former. Previous studies adopted a 343 
similar approach to assess concurrent validity of new molecular pain indicators or to 344 
investigate the effectiveness of pain mitigation methods in laboratory animals (Amin et al., 345 
2014, Tiwari et al. 2012) or in dairy cattle (Rialland et al., 2013). The authors generally 346 
reported that combining behavioural and molecular biomarkers meaningfully contributed in 347 
providing a global picture of the animal’s state. For the first time this paper addressed this 348 
question in horses: interestingly, positive correlations were found between miRNA 349 
expression levels and other non-invasive pain measures based on observation of horse 350 
demeanour (HGS and CPS). These findings suggest directions for a more accurate pain 351 
assessment that may help the equine clinician focus onto the peculiar issue of animal 352 
welfare in the course of laminitis. This implies, for example, acceptance or refusal of long 353 
lasting pain and suffering, likely to range from weeks to months, even in the presence of 354 
medical treatment. Our results suggest that an integrated analysis of non-invasive pain 355 
measures (CPS, HGS) and molecular biomarkers may be useful for more reliable 356 
assessment and monitoring of painful conditions.  357 
Pathway enrichment of the predicted targets of the differentially expressed (DE)-miRNAs 358 
was identified. Despite the differences in the lists of genes targeted by DE-miRNAs, the 359 
glutamatergic pathway was found to be enriched by all DE-miRNAs. Glutamate is the 360 
major excitatory neurotransmitter in the mammalian central nervous system and mediates 361 
many aspects of sensory function, including acute and chronic pain in both humans and 362 
animals (Stephens, 2011; Brearley, 2000). After release from presynaptic nerve terminals, 363 
glutamate is quickly removed from the synaptic cleft by a family of five glutamate 364 
transporters, the excitatory amino acid transporters (EAATs) (Fahlke et al., 2016). Our 365 
analysis demonstrated that EAATs might be regulated by DE-miRNAs. EAATs belong to 366 
solute carrier 1 family (SLC) and they can function both as transporters, by mediating the 367 
re-uptake of synaptic released glutamate, and as anion-selective channels (Fahlke et al., 368 
2016). Since glutamate is the major excitatory neurotransmitter released in the first central 369 
synapse of the pain-transmitting afferent neurons, the modulation of transporters and ion 370 
channels activities, which regulate extracellular levels of glutamate, may be an important 371 
target for pain management strategies both in humans and in animals (Stephens, 2011; 372 
Brearley, 2000). An excessive accumulation of extracellular glutamate is implicated in the 373 
pathogenesis of trauma, ischemia, and neurodegenerative diseases in humans (Kim et al., 374 
2011). The modulation of EAATs by de-miRNAs as identified in the present study might 375 
involve decrease in glutamate re-uptake leading to excitotossicity and neuronal damage 376 
(Kim et al., 2011). A previous study demonstrated that neuronal exosomal miR-124a 377 
regulates the expression of EAAT2 by modulation of translation process in mice (Morel et 378 
al., 2013). Although miR-124a resulted not expressed in our model, the outcomes reported 379 
by Morel and colleagues (2013) demonstrated that miRNAs are involved in the regulation 380 
of EAATs and, consequently, in glutamate re-uptake. Augmentation of synaptic strength in 381 
nociceptive pathways represents a cellular model of pain amplification (Clark et al., 2015). 382 
Ding et colleagues (2017) demonstrated that miRNAs modulate the expression levels of 383 
NMDA receptor during chronic pain in rats. Our data may therefore suggest that, under 384 
chronic pain formation, the activation of NMDA receptors (mediated by miR-23b-3p, miR-385 
145-5p and miR-200b-3p overexpression) may drive the facilitation of excitatory synaptic 386 
transmission in the dorsal horn, which contributes to maintaining allodynic and 387 
hyperalgesic pain in chronic pain states. Given that miR-200b-3p expression is restored to 388 
the control group level in animals affected by acute laminitis after treatment, the predicted 389 
targets of this miRNA was investigated using KEGG bioinformatics sources. Interestingly, 390 
the GABAergic pathway was found to be enriched. GABA is the main inhibitory transmitter 391 
of the nervous system and GABA receptors play important roles in the dampening of 392 
neuropathic hyperexcitability by depolarizing neurons, thus blocking the information 393 
transmission from dorsal root ganglia to the spinal cord (Gwak and Hulsebosch, 2011). 394 
Naik and colleagues (2008) demonstrated that GABA receptors are down-regulated in 395 
injured neurons after spinal nerve injury in rats and hypothesised that they play an 396 
important role in the development of increased synaptic transmission in neuropathic pain. 397 
The influence of miRNAs on GABA receptors has been previously demonstrated, i.e. miR-398 
33 regulates hippocampal extrasynaptic GABAA receptors in a mouse model of contextual 399 
fear conditioning (Jovasevic et al., 2015) and miR-181a down-regulates GABA(Aα-1) 400 
receptor in adult spinal cords from rats with neonatal cystitis (Sengupta et al., 2013). We 401 
speculate that high levels of miR-200b-3p might downregulate the expression of GABA 402 
receptors during acute phase of laminitis, while the inhibition of miRNA expression after 403 
treatment might increase receptor density and thus sensitivity of GABA receptors. 404 
The present study has some limitations to be pointed out. Its sample size is hampered 405 
because accessing cases of horses with acute laminitis having no prior treatment is 406 
difficult. However, conducting this initial study on a limited number of animals showed the 407 
advantage of testing the research design adequacy in view of future larger scale studies. 408 
G-Power analysis suggests that clinical studies involving more than 20 horses per group 409 
are needed to confirm the diagnostic value of DE-miRNAs for acute laminitis. Moreover, 410 
future studies should elucidate whether DE-miRNAs could further discriminate between 411 
pain induced by laminitis and other acute or chronic pain conditions. In addition, exosome-412 
mediated transfer of miRNAs may be involved in cell-to-cell communication (Valadi et al., 413 
2007). The underlying functions in intracellular communication of miRNAs identified in the 414 
present study and their possible roles in the pathophysiological processes of laminitis 415 
remain unknown. A possible limitation of the use of HGS is that still images taken from 416 
videos may not accurately reflect the potentially changing nature of facial expressions in 417 
real time. Based on methods adopted in previous publications, this study only considered 418 
one image per animal per time point. It is suggested that future studies include more high 419 
quality images or videos of the horse head.Tackling the challenge of improving the welfare 420 
of horses affected by laminitis, for the first time our study investigated the dynamic 421 
expressions of circulating miRNAs during the acute phase of the disease. ROC analysis 422 
suggested that circulating miR-23b-3p, miR-200b-3p and miR-145-5p might be considered 423 
novel and promising biomarkers for early diagnosis of acute pain in horses. Eventually, a 424 
multi-miRNa panel including miR-200b-3p and miR-145-5p might present even greater 425 
diagnostic value and be meaningfully applied to the validation of behavioural pain 426 
measures. 427 
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 580 
Figure 1. Box plots for circulating pain-related miRNAs levels: (A) miR-23b-3p, (B) miR-200b-3p, 581 
(C) miR-146a-5p, (D) miR-181a-5p and (E) miR-145-5p. Different letters (a, b, ab) indicate 582 
significant differences among the groups (Control, Pre-treatment and Post-treatment) with a 583 
significance level at P < 0.05. The black lines inside the boxes mark the medians. Whiskers 584 
indicate variability outside the upper and lower quartiles. 585 
586 
 587 
Figure 2. Receiver-operator characteristics (ROC) curve analysis of candidate pain-related 588 
miRNAs. AUC, area under the curve; CI, confidence interval. 589 
 590 
 591 
Figure 3. CPS and HGS scores of the control, pre-treatment and post-treatment groups drawn in a 592 
box plot. Differences between the groups (Control, Pre-treatment and Post-treatment) are indicated 593 
as follows: *** P < 0.000. The black lines inside the boxes mark the medians. Whiskers indicate 594 
variability outside the upper and lower quartiles. Circles, labelled with the individual case numbers, 595 




Figure 4. Predicted mRNA targets for DE-miRNAs. (A) Venn diagram showing the genes that are 600 
potential targets of DE-miRNAs; (B) TargetScan software was used to identify potential mRNA 601 
targets. The list was filtered by selecting those genes that encode for ion channels: solute carrier 602 
family transporters (SLC), potassium voltage-gated channel (KCN), voltage-gated sodium channel 603 
(SCN), gamma-aminobutyric acid (GABA) receptor, voltage-dependent calcium channel (CACN), 604 
adrenoceptor alpha (ADRA), potassium channel (tetramerization domain) (KCTD), 605 
hyperpolarization activated cyclic nucleotide-gated potassium channel (HCN), two pore segment 606 
channel (TPCN), transient receptor potential cation channel (TRP). (C) Glutamatergic pathway 607 
identified by KEGG pathway analysis using the mRNA targets. Proteins coded by mRNA targets 608 
genes are highlighted in red. GLNT and EAAT belong to solute carrier family transporters (SLC); 609 
VGCC to voltage-dependent calcium channel (CACN). 610 
 611 
